Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.

You are here:Home-ADCs and PROTACs-Antibody-drug conjugate (ADCs)-Trastuzumab deruxtecan
Trastuzumab deruxtecan

Chemical Structure : Trastuzumab deruxtecan

CAS No.: 1826843-81-5

Trastuzumab deruxtecan (T-DXd, DS-8201, DS-8201a, DS8201)

Catalog No.: PC-28465Not For Human Use, Lab Use Only.

Trastuzumab deruxtecan (T-DXd, DS-8201a) is a HER2-targeting antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd) at a drug-to-antibody ratio (DAR) of 7-8, shows potent antitumor activity HER2-positive cancers.

Packing Price Stock Quantity
1 mg $398 In stock
2 mg $598 In stock
5 mg Get quote
10 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Trastuzumab deruxtecan (T-DXd, DS-8201a) is a HER2-targeting antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd) at a drug-to-antibody ratio (DAR) of 7-8, shows potent antitumor activity HER2-positive cancers.
Trastuzumab deruxtecan (T-DXd, DS-8201a) exhibits a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-positive gastric cancer NCI-N87 model. Trastuzumab deruxtecan (T-DXd, DS-8201a) also shows an inhibitory activity to Akt phosphorylation.
Trastuzumab deruxtecan (T-DXd, DS-8201a) induces phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage. effective in a T-DM1-insensitive PDX model with high HER2 expression.

Physicochemical Properties

M.Wt 153000 (average)
Formula
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

References

1. Nagai Y, et al. Xenobiotica. 2019 Sep;49(9):1086-1096.

2. Iwata TN, et al. Mol Cancer Ther. 2018 Jul;17(7):1494-1503.

3. Ogitani Y, et al. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: